Services (List) | UCLA Stem Cell Engr.

Services

The UCLA Human Stem Cell and Genome Engineering Center provides investigators with access to advanced stem cell engineering and genome editing technologies to support biomedical research and therapeutic discovery. Our integrated platform enables the generation of patient-specific induced pluripotent stem cells (iPSCs), precise genome engineering, and comprehensive genomic quality control to ensure the reliability of engineered cell models.

These services support a wide range of applications including disease modeling, functional genomics, and drug discovery. In addition to core capabilities available within the center, investigators may also access specialized assays and extended technologies through collaborating institutes and partner core facilities.

General Inquiries: StemCellEngineering@mednet.ucla.edu
Hyokyeong Cha, PhD Stem Cell Activities Manager: hyokyeongcha@mednet.ucla.edu
Deniz Ata, PhD Gene Editing Activities Manager: data@mednet.ucla.edu

UC - Internal Request Form

Copy Number Variation Analysis

Copy number variation (CNV) analysis is performed using low-pass whole genome sequencing to assess genomic integrity in induced pluripotent stem cell (iPSC) lines and genetically engineered cell lines. This approach enables detection of large-scale chromosomal abnormalities and genomic copy number changes that may arise during reprogramming, genome editing, or long-term cell culture.

CNV analysis provides a rapid and cost-effective method for screening cell lines prior to banking, validating genome editing outcomes, and monitoring genomic stability during experimental workflows.

Starting Material: Cell Pellet or Genomic DNA (gDNA)

Estimated Completion Time: 4 - 6 Weeks

Project Deliverables: Genome-wide CNV profile and Analysis Report
For Details Contact: hyokyeongcha@mednet.ucla.edu

Sample Service Report

ipsc 1-1 ssea4-merged 1_edited_edited_edited.png

Stem Cell Genome Editing

Genome engineering services are available for induced pluripotent stem cells (iPSCs) using CRISPR-based technologies and related genome editing platforms. These approaches enable precise genetic modifications, including gene knockouts, targeted insertions, reporter integration, and correction or introduction of disease-associated mutations.

Genome editing in iPSCs enables the generation of isogenic cell models for studying gene function, investigating disease mechanisms, and validating therapeutic targets. Edited cell lines can be expanded and characterized for downstream applications including differentiation studies, functional genomics, and drug discovery.

Starting Material: Stem Cell Lines

Estimated Completion Time: 4 - 6 Months

Project Deliverables: Minimum 3 Clones + Characterization Report
For Details Contact: data@mednet.ucla.edu

Click for List of Services

Sample Service Report

iPSC Reprogramming

Induced pluripotent stem cells (iPSCs) are generated from patient-derived cells, such as fibroblasts or peripheral blood mononuclear cells, using integration-free reprogramming methods. These approaches avoid genomic integration of reprogramming factors, preserving genomic integrity and ensuring compatibility with downstream applications. The resulting iPSC lines provide stable, expandable cell models that can be used for disease modeling, genome editing, differentiation studies, and drug discovery.

Starting Material: PBMC / Fibroblast

Estimated Completion Time: 3 - 4 Months

Project Deliverables: Minimum 3 Clones + Characterization Report
For Details Contact: hyokyeongcha@mednet.ucla.edu

Sample Service Report

Services Provided by Collaboration Network Partners

The UCLA Human Stem Cell and Genome Engineering Center is part of a broader network of UCLA core facilities and collaborating research groups. For specialized services not currently available within the center, investigators may be referred to partner facilities that provide complementary capabilities.

These collaborations enable access to additional technologies including animal model generation, advanced sequencing platforms, in vivo experimental systems, and specialized functional assays, supporting comprehensive research workflows from engineered cell line development to downstream biological validation.

TBA